SEC Form 4/A · accession 0001209191-18-005355
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Dec 1, 2017
Accepted (ET)
Jan 25, 2018 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F3,F2 | $0.3025 | Dec 1, 2017 | M | 6,000 | D | — | Aug 12, 2019 | Common stock | 6,000 | 38,837 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on August 1, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.
- F3The original Form 4, filed on December 5, 2017, is being amended by this Form 4 amendment solely to correct the number of derivative securities beneficially owned following reported transaction.